Jan Alsner

List of Publications by Year in Descending Order

140 papers	6,597 citations	49 h-index	78 g-index
161 ext. papers	7,541 ext. citations	3.7 avg, IF	5.41 L-index

#	Paper	IF	Citations
140	Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. *Radiotherapy and Oncology*, **2021**,	5.3	1
139	Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts. *International Journal of Cancer*, **2021**,	7.5	1
138	Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort. *Acta Oncologica*, **2021**, 1-10	3.2	1
137	Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: A population-based Danish Breast Cancer Group study. *Radiotherapy and Oncology*, **2021**, 157, 106-113	5.3	11
136	Patient-reported outcomes in postmenopausal breast cancer survivors - comparisons with normative data. *Acta Oncologica*, **2021**, 60, 78-86	3.2	2
135	Correlation and prognostic impact of human papilloma virus and p16-expression in advanced hypopharynx and larynx cancer treated with definitive radiotherapy. *Acta Oncologica*, **2021**, 60, 646-648	3.2	0
134	Effect of patient-reported outcomes as a dialogue-based tool in cancer consultations on patient self-management and health-related quality of life: a clinical, controlled trial. *Acta Oncologica*, **2021**, 60, 1668-1677	3.2	0
133	Living with heritable retinoblastoma and the perceived role of regular follow-up at a retinoblastoma survivorship clinic: 'That is exactly what I have been missing' *BMJ Open Ophthalmology*, **2021**, 6, e000760	3.2	0
132	Hypoxic gene expression is a prognostic factor for disease free survival in a cohort of locally advanced squamous cell cancer of the uterine cervix. *Acta Oncologica*, **2021**, 1-7	3.2	1
131	Symptom trajectories in breast cancer survivors: growth mixture analysis of patient-reported pain, fatigue, insomnia, breast and arm symptoms. *Acta Oncologica*, **2021**, 60, 1659-1667	3.2	2
130	Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013. *JAMA Network Open*, **2020**, 3, e2022126	10.4	9
129	Specific requirements for translation of biological research into clinical radiation oncology. *Molecular Oncology*, **2020**, 14, 1569-1576	7.9	4
128	Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. *Journal of Clinical Oncology*, **2020**, 38, 3615-3625	2.2	54
127	Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts. *Acta Oncologica*, **2019**, 58, 1489-1494	3.2	13
126	Molecular Biomarkers in Radiation Oncology **2019**, 1-20		2
125	Comparison of Coding Transcriptomes in Fibroblasts Irradiated With Low and High LET Proton Beams and Cobalt-60 Photons. *International Journal of Radiation Oncology Biology Physics*, **2019**, 103, 1203-1211	4	4
124	Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC). *Radiotherapy and Oncology*, **2019**, 130, 191-192	5.3	2

123	DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. *Radiotherapy and Oncology*, **2018**, 127, 12-19	5.3	16
122	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. *Acta Oncologica*, **2018**, 57, 38-43	3.2	15
121	Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer. *Acta Oncologica*, **2018**, 57, 102-106	3.2	8
120	Optimal reference genes for normalization of qPCR gene expression data from proton and photon irradiated dermal fibroblasts. *Scientific Reports*, **2018**, 8, 12688	4.9	3
119	Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial. *Acta Oncologica*, **2018**, 57, 1159-1164	3.2	5
118	Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients. *Clinical and Translational Radiation Oncology*, **2017**, 2, 46-52	4.6	5
117	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. *Clinical Cancer Research*, **2017**, 23, 4761-4768	12.9	70
116	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. *Breast Cancer Research*, **2017**, 19, 44	8.3	57
115	Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. *Acta Oncologica*, **2017**, 56, 1514-1521	3.2	5
114	Differential gene expression in primary fibroblasts induced by proton and cobalt-60 beam irradiation. *Acta Oncologica*, **2017**, 56, 1406-1412	3.2	15
113	Rethink radiotherapy - BIGART 2017. *Acta Oncologica*, **2017**, 56, 1341-1352	3.2	3
112	Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. *Acta Oncologica*, **2017**, 56, 59-67	3.2	14
111	Relative Biological Effectiveness of Antiprotons the AD-4/ACE Experiment **2017**,		1
110	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. *Radiotherapy and Oncology*, **2016**, 121, 431-439	5.3	69
109	Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer. *Clinical Cancer Research*, **2016**, 22, 4067-76	12.9	30
108	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. *Clinical Cancer Research*, **2016**, 22, 2639-49	12.9	88
107	Radiogenomics - current status, challenges and future directions. *Cancer Letters*, **2016**, 382, 127-136	9.9	52
106	Danish retinoblastoma patients 1943-2013 - genetic testing and clinical implications. *Acta Oncologica*, **2016**, 55, 412-7	3.2	7

105	Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer. *PLoS ONE*, **2016**, 11, e0148070	3.7	6
104	Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients. *Radiotherapy and Oncology*, **2016**, 120, 98-106	5.3	12
103	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *Radiotherapy and Oncology*, **2016**, 121, 364-373	5.3	80
102	Radiation-induced morbidity evaluated by high-frequency ultrasound. *Acta Oncologica*, **2016**, 55, 1498-1500	3.2	3
101	The relative biological effectiveness of antiprotons. *Radiotherapy and Oncology*, **2016**, 121, 453-458	5.3	4
100	Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. *Acta Oncologica*, **2016**, 55, 1091-1098	3.2	48
99	An evaluation of multiplex bead-based analysis of cytokines and soluble proteins in archived lithium heparin plasma, EDTA plasma and serum samples. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2016**, 76, 601-611	2	16
98	A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma. *British Journal of Cancer*, **2016**, 115, 1096-1104	8.7	7
97	Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer. *Anticancer Research*, **2016**, 36, 721-30	2.3	4
96	Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication. *Anticancer Research*, **2016**, 36, 749-56	2.3	5
95	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. *Radiotherapy and Oncology*, **2015**, 116, 346-51	5.3	22
94	Validation of a gene expression profile predictive of the risk of radiation-induced fibrosis in women treated with breast conserving therapy. *Acta Oncologica*, **2015**, 54, 1665-8	3.2	7
93	Relative biological effectiveness of carbon ions for tumor control, acute skin damage and late radiation-induced fibrosis in a mouse model. *Acta Oncologica*, **2015**, 54, 1623-30	3.2	27
92	Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. *Acta Oncologica*, **2015**, 54, 1582-91	3.2	29
91	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2015**, 30, 689-721	5.6	79
90	Differential protein expression of peroxiredoxin-1 in classical Hodgkin Lymphoma: a possible correlation to clinical behaviour. *Hematological Oncology*, **2015**, 33, 253-5	1.3	1
89	Simultaneous Hypoxia and Low Extracellular pH Suppress Overall Metabolic Rate and Protein Synthesis In Vitro. *PLoS ONE*, **2015**, 10, e0134955	3.7	15
88	Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. *British Journal of Cancer*, **2014**, 110, 2072-80	8.7	89

87	The importance of reference gene analysis of formalin-fixed, paraffin-embedded samples from sarcoma patients - an often underestimated problem. *Translational Oncology*, **2014**, 7, 687-93	4.9	12
86	Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort. *Clinical Cancer Research*, **2014**, 20, 5272-80	12.9	63
85	Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. *Acta Oncologica*, **2014**, 53, 1337-46	3.2	28
84	Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. *Oncoscience*, **2014**, 1, 367-74	0.8	57
83	Hypoxia and Radiation Therapy. *Cancer Drug Discovery and Development*, **2014**, 265-281	0.3	1
82	Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo models. *Anticancer Research*, **2014**, 34, 6297-304	2.3	13
81	Identification of accurate reference genes for RT-qPCR analysis of formalin-fixed paraffin-embedded tissue from primary non-small cell lung cancers and brain and lymph node metastases. *Lung Cancer*, **2013**, 81, 180-6	5.9	33
80	Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. *Radiotherapy and Oncology*, **2013**, 108, 500-5	5.3	78
79	Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2013**, 463, 775-86	5.1	10
78	SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 791-9	4	39
77	Independent prospective validation of a predictive test for risk of radiation induced fibrosis based on the gene expression pattern in fibroblasts irradiated in vitro. *Radiotherapy and Oncology*, **2013**, 108, 469-72	5.3	16
76	Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. *Molecular Oncology*, **2013**, 7, 704-18	7.9	57
75	Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model. *Acta Oncologica*, **2013**, 52, 1730-8	3.2	17
74	Hypoxia-regulated gene expression and prognosis in loco-regional gastroesophageal cancer. *Acta Oncologica*, **2013**, 52, 1327-35	3.2	10
73	Optimal reference genes for normalization of qRT-PCR data from archival formalin-fixed, paraffin-embedded breast tumors controlling for tumor cell content and decay of mRNA. *Diagnostic Molecular Pathology*, **2013**, 22, 181-7		20
72	Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. *Genome Biology*, **2013**, 14, R126	18.3	65
71	Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. *Seminars in Radiation Oncology*, **2012**, 22, 119-27	5.5	57
70	Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. *Radiotherapy and Oncology*, **2012**, 102, 122-9	5.3	167

69	Conducting radiogenomic research--do not forget careful consideration of the clinical data. *Radiotherapy and Oncology*, **2012**, 105, 337-40	5.3	26
68	Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. *Radiotherapy and Oncology*, **2012**, 105, 289-95	5.3	52
67	FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. *Radiotherapy and Oncology*, **2012**, 105, 14-20	5.3	231
66	Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer. *Scandinavian Journal of Immunology*, **2011**, 73, 122-7	3.4	20
65	In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors. *BMC Cancer*, **2011**, 11, 63	4.8	10
64	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. *Clinical Proteomics*, **2011**, 8, 11	5	79
63	Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. *Cancer Research*, **2011**, 71, 5923-31	10.1	183
62	In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome. *PLoS ONE*, **2010**, 5, e14002	3.7	20
61	HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. *Radiotherapy and Oncology*, **2010**, 94, 30-5	5.3	155
60	Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNF prevents radiation-induced fibrosis. *Radiotherapy and Oncology*, **2010**, 97, 143-8	5.3	48
59	Biodistribution of 99mTc-HYNIC-lactadherin in mice--a potential tracer for visualizing apoptosis in vivo. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2010**, 70, 209-16	2	13
58	Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. *Acta Oncologica*, **2010**, 49, 895-905	3.2	52
57	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. *Clinical Proteomics*, **2010**, 6, 129-51	5	170
56	Establishment of a Radiogenomics Consortium. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 1295-6	4	98
55	Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. *Clinical Cancer Research*, **2009**, 15, 3654-62	12.9	109
54	Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. *Journal of Clinical Oncology*, **2009**, 27, 1992-8	2.2	482
53	Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics. *Radiotherapy and Oncology*, **2009**, 92, 443-9	5.3	28
52	Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. *Radiotherapy and Oncology*, **2009**, 92, 299-309	5.3	139

51	Genetic markers for prediction of normal tissue toxicity after radiotherapy. *Seminars in Radiation Oncology*, **2008**, 18, 126-35	5.5	90
50	Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials. *Breast Cancer Research*, **2008**, 10, R24	8.3	14
49	Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. *Radiotherapy and Oncology*, **2008**, 86, 314-20	5.3	65
48	Antiproton radiotherapy. *Radiotherapy and Oncology*, **2008**, 86, 14-9	5.3	24
47	A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. *Acta Oncologica*, **2008**, 47, 618-32	3.2	21
46	A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. *Acta Oncologica*, **2008**, 47, 600-7	3.2	72
45	Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. *Acta Oncologica*, **2008**, 47, 608-17	3.2	22
44	The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models. *Acta Oncologica*, **2008**, 47, 941-7	3.2	18
43	Transformation of human mesenchymal stem cells in radiation carcinogenesis: long-term effect of ionizing radiation. *Regenerative Medicine*, **2008**, 3, 849-61	2.5	29
42	Antiproton therapy. *Nuclear Instruments & Methods in Physics Research B*, **2008**, 266, 530-534	1.2	11
41	Reproductive death of cancer cells induced by femtosecond laser pulses. *International Journal of Radiation Biology*, **2007**, 83, 289-99	2.9	5
40	Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart. *Experimental Cell Research*, **2007**, 313, 1056-67	4.2	49
39	Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. *Radiotherapy and Oncology*, **2007**, 83, 389-97	5.3	71
38	Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. *Radiotherapy and Oncology*, **2007**, 83, 362-6	5.3	56
37	Differential gene expression before and after ionizing radiation of subcutaneous fibroblasts identifies breast cancer patients resistant to radiation-induced fibrosis. *Radiotherapy and Oncology*, **2007**, 83, 261-6	5.3	36
36	900 ORAL Are TGF-beta 1 polymorphisms potential predictors of fibrosis risk after radiotherapy? a subset analysis from the DAHANCA 6 and 7 protocols. *European Journal of Cancer, Supplement*, **2007**, 5, 119	1.6	2
35	Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. *European Urology*, **2006**, 50, 777-85	10.2	22
34	LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. *Acta Oncologica*, **2006**, 45, 602-9	3.2	15

33	Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM--a study based on DNA from formalin fixed paraffin embedded tissue samples. *International Journal of Radiation Biology*, **2006**, 82, 577-86	2.9	92
32	Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. *Radiotherapy and Oncology*, **2006**, 80, 165-71	5.3	9
31	ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 776-83	4	83
30	Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. *Lancet Oncology, The*, **2005**, 6, 757-64	21.7	244
29	TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. *Radiotherapy and Oncology*, **2005**, 75, 18-21	5.3	104
28	The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. *Radiotherapy and Oncology*, **2005**, 76, 135-42	5.3	24
27	Influence of oxygen concentration and pH on expression of hypoxia induced genes. *Radiotherapy and Oncology*, **2005**, 76, 187-93	5.3	103
26	Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts. *Radiotherapy and Oncology*, **2005**, 77, 231-40	5.3	72
25	Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum. *International Journal of Radiation Biology*, **2005**, 81, 937-44	2.9	17
24	Prognostic value genotypes and LOH at TP53 codon 72 and TP53mutations in primary breast cancer. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
23	Application of microarray analyses to identify genes involved in radiation-induced fibrosis. *Breast Cancer Research*, **2005**, 7, 1	8.3	1
22	The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 561-6	4	92
21	Optimisation and validation of methods to assess single nucleotide polymorphisms (SNPs) in archival histological material. *Radiotherapy and Oncology*, **2004**, 72, 351-6	5.3	19
20	Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. *Radiotherapy and Oncology*, **2004**, 72, 275-82	5.3	36
19	Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer. *British Journal of Cancer*, **2003**, 89, 298-304	8.7	21
18	Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. *Radiotherapy and Oncology*, **2003**, 69, 127-35	5.3	184
17	Does variability in normal tissue reactions after radiotherapy have a genetic basis--where and how to look for it?. *Radiotherapy and Oncology*, **2002**, 64, 131-40	5.3	144
16	Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 519-25	4	16

15	Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. *British Journal of Cancer*, **2001**, 84, 1070-5	8.7	173
14	TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. *Radiotherapy and Oncology*, **2001**, 59, 179-85	5.3	80
13	An evolutionary-game model of tumour-cell interactions: possible relevance to gene therapy. *European Journal of Cancer*, **2001**, 37, 2116-20	7.5	49
12	Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. *Rays*, **2000**, 25, 313-9		26
11	Activation of peroxisome proliferator-activated receptor gamma bypasses the function of the retinoblastoma protein in adipocyte differentiation. *Journal of Biological Chemistry*, **1999**, 274, 2386-93	5.4	122
10	The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. *Acta Oncologica*, **1998**, 37, 441-5	3.2	13
9	Topoisomerase II-mediated DNA cleavage: evidence for distinct regions of enzyme-DNA contacts. *Journal of Molecular Biology*, **1996**, 259, 317-24	6.5	6
8	Intramolecular and intermolecular DNA ligation mediated by topoisomerase II. *Journal of Molecular Biology*, **1994**, 241, 18-25	6.5	11
7	Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. *Biochemical Pharmacology*, **1994**, 47, 2105-10	6	20
6	Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. *Nucleic Acids Research*, **1993**, 21, 593-600	20.1	41
5	A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution. *FEBS Journal*, **1993**, 218, 575-84		12
4	Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. *Journal of Molecular Biology*, **1992**, 228, 1025-30	6.5	71
3	Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. *Journal of Molecular Biology*, **1992**, 228, 778-86	6.5	106
2	Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. *Biochemistry*, **1990**, 29, 5613-9	3.2	114
1	Stimulation of topoisomerase II mediated DNA cleavage at specific sequence elements by the 2-nitroimidazole Ro 15-0216. *Biochemistry*, **1990**, 29, 9507-15	3.2	24